Matrix metalloproteinase-3 mRNA (MMP3 mRNA) (MMP3 mRNA)

Matrix metalloproteinase-3 (MMP3) mRNA is the transcript that encodes the enzyme Stromelysin-1, a key mediator in the degradation of the extracellular matrix (ECM). This enzyme targets a wide range of substrates, including proteoglycans, laminin, fibronectin, and various collagen types, and it also serves as an activator for other pro-MMPs like pro-MMP1 [UniProt P08254]. In chronic inflammatory and degenerative diseases such as osteoarthritis and rheumatoid arthritis, the overexpression of MMP3 mRNA leads to excessive enzyme production, which drives the breakdown of articular cartilage and joint destruction [PubMed PMID: 15640486]. Targeting the mRNA directly via RNA interference (RNAi) or antisense technology offers a highly specific therapeutic approach compared to traditional small-molecule inhibitors, which often suffer from poor selectivity across the MMP family [NCBI Gene 4314]. By silencing the gene at the pre-translational level, these therapies aim to reduce the pathological burden of MMP3 while minimizing systemic toxicity. Current research is particularly focused on local delivery methods, such as intra-articular injections, to treat localized joint degeneration [PubMed PMID: 15640486]. This target represents a shift toward precision medicine in rheumatology and oncology, where sequence-specific knockdown can bypass the structural similarities that plague enzyme-level inhibition [PubMed PMID: 23454142].

Other names

Stromelysin-1 mRNASL-1 mRNAMatrix metallopeptidase 3 mRNATransin-1 mRNA

RNA interference (RNAi) and antisense-mediated mRNA degradation to prevent translation of the MMP3 enzyme.